

## **Cesarean Delivery Thromboprophylaxis**

### **Background**

Pregnancy is a state of physiologic hypercoagulability. Pulmonary embolism is a leading cause of maternal mortality. The postpartum period is the time of highest risk for venous thromboembolic disease (VTE). Cesarean delivery, especially when performed emergently, is associated with a higher risk of VTE than vaginal delivery. VTE occurs in up to 0.7% of women undergoing the operation, most of whom are asymptomatic. However, the absolute risk remains low (about 1 per 1,000 or less).

The use of intermittent pneumatic compression devices reduces the risk of VTE by at least 50%, and are a cost-effective (\$37 per device) intervention. (ACOG Practice Bulletin No. 84, Appelen-Cochrane Database) Early ambulation is also to be encouraged. Low molecular weight heparin is considered the drug of choice for this situation because of the safety and efficacy profile. The recommended regimen for prophylactic low molecular weight heparin in high-risk women undergoing cesarean delivery is subcutaneous enoxaparin. Heparin pharmacokinetics in pregnancy are largely determined by renal clearance, not volume of distribution.

### **Risk Factors**

Post-cesarean use of prophylactic low molecular weight heparin is not associated with an increased risk of postoperative bleeding (0.4%), but is accompanied by a small (0.1%) risk of heparin induced thrombocytopenia. While it is not recommended for low risk women undergoing cesarean delivery, it may be warranted for women with additional risk factors. The American College of Chest Physicians (ACCP) risk factors include:

#### **ACCP, major risk factors**

- strict bedrest for  $\geq 1$  week antepartum
- bleeding  $\geq 1000$  mL at cesarean
- previous VTE
- preeclampsia with fetal growth restriction
- antithrombin deficiency
- factor V Leiden (homozygous or heterozygous)
- prothrombin G20210A (homozygous or heterozygous)
- blood transfusion
- infection
- Lupus, heart disease
- Sickle cell disease

#### **ACCP, minor risk factors**

- BMI  $>30$  kg/m<sup>2</sup>
- multiple gestation
- postpartum hemorrhage  $>1000$  mL
- smoking  $>10$  cigarettes/day
- birth weight  $<25$ th centile
- protein C or S deficiency
- preeclampsia

## **I. Management: Short term**

### **A. Baseline intervention**

- Early ambulation
- Intermittent pneumatic compression devices
- Consider consultation with PT to assist in early mobilization of super-obese patients

### **B. Pharmacologic thromboprophylaxis**

Begin pharmacologic therapy if:

- One major ACCP risk factor for VTE  
or
- Two minor ACCP risk factors for VTE

Treatment will consist of:

#### **BMI < 50 kg/M<sup>2</sup>**

Enoxaparin (Lovenox) 40 mg subcutaneous q 12 hrs, starting 12 hrs post op

#### **BMI > 50 kg/M<sup>2</sup>**

Enoxaparin (Lovenox) 60 mg subcutaneous q 12 hrs, starting 12 hrs post op

### **B. High Risk**

(multiple episodes of VTE, or anti-thrombin III deficiency)

Individualize care

Weight-based dosing is superior to fixed dosing, eg, enoxaparin 0.5 mg/kg every 12 hours

## **II. Management: Long term**

### **A. Baseline intervention**

Treatment in hospital only

### **B. High Risk**

Care should be individualized

Warfarin, Enoxaparin, and antiplatelet agent therapy have been described in various clinical situations.

## **References**

1. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2018;132:e1—17.
2. Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2018;132:e1—17.
3. Duhl A, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. *Am J Obstet Gynecol* 2007; 457.e1-457.e21.

4. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. American College of Chest Physicians. Chest. 2012 Feb;141(2 Suppl):e691S-736S
5. Greer IA, et al. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-
6. Casele H, et al. Cost-effectiveness of thromboprophylaxis with intermittent pneumatic compression at cesarean delivery. Obstet Gynecol 2006; 108:535-40.
7. Che Yaakob CA, Dzarr AA, Ismail AA, Zuky Nik Lah NA, Ho JJ. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD007801. DOI: 10.1002/14651858. CD007801.pub2.
8. Bain E, Wilson A, Toohar R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD001689. DOI: 10.1002/14651858.CD001689.pub3.
9. Appelen D, van Loo E, Prins MH, Neumann MHAM, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD004174. DOI: 10.1002/14651858.CD004174.pub3.

Reviewed 7/6/18 njm  
Revised 4/23/16njm  
Revised 2/7/14njm  
Revised 9/25/11njm  
Approved 1/5/11njm